|
Vaccine Detail
MART-1/gp100/Tyrosinase/MAGE-A3 Peptides-loaded Irradiated Allogeneic Plasmacytoid Dendritic Cells Vaccine |
Vaccine Information |
- Vaccine Name: MART-1/gp100/Tyrosinase/MAGE-A3 Peptides-loaded Irradiated Allogeneic Plasmacytoid Dendritic Cells Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007505
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: PMEL, MAGEA3, MLANA
- gp100 (PMEL)
gene engineering:
- MAGEA3
gene engineering:
- MLANA
gene engineering:
- Preparation: pDCs were loaded with tumor-derived HLA-A*0201-restricted peptides and the corresponding iTag HLA-A*0201 tetramers : MelA26–35 (ELAGIGILTV), GP100209–217 (IMDQVPFSV), tyrosinase369–377 (YMDGTMSQV), and MAGE-A3271–279 (FLWGPRALV) (Aspord et al., 2012).
- Description: Irradiated allogeneic, HLA-A*0201 positive, plasmacytoid dendritic cells (pDCs) loaded with 4 melanoma peptides derived from the tumor associated antigens (TAAs) MelA/MART-1, gp100/pmel17, tyrosinase, and MAGE-A3, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the irradiated allogeneic pDCs may trigger functional multi-specific T cells from peripheral blood mononuclear cells and tumor-infiltrating lymphocytes, and activate the immune system to mount a cytotoxic T-lymphocyte response against HLA-A*0201 positive melanoma cancer cells expressing the TAAs MelA/MART-1, gp100/pmel17, tyrosinase, and MAGE-A3. These TAAs are upregulated in a variety of tumor cells. The pDCs are derived from a distinct subset of dendritic cells (DCs) with a plasma cell-like morphology and express a characteristic set of surface markers and may increase the anti-tumor immune responses. (NCIT_C107159).
|
Host Response |
|
References |
Aspord et al., 2012: Aspord C, Leccia MT, Salameire D, Laurin D, Chaperot L, Charles J, Plumas J. HLA-A(*)0201(+) plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients. The Journal of investigative dermatology. 2012; 132(10); 2395-2406. [PubMed: 22696054].
NCIT_C107159: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C107159]
|
|